Rachael Walker

Rachael Walker
Rachael Walker
Rachael Walker
Head of Flow Cytometry Facility
Rachael Walker

Head of Flow Cytometry: Dr Rachael Walker

Building 580, Babraham Institute, Babraham Research Campus, Cambridge, CB22 3AT
rachael.walker@babraham.ac.uk
01223 496559

Rachael has over 15 years of experience in flow cytometry and cell sorting and over a dozen years of working in flow cytometry core facilities. Rachael joined the core in September 2012, following 7 years running Flow Cytometry Core Facilities at the University of Cambridge.

Rachael has extensive experience in analysis and sorting cells of differing types including; immunology, cell biology, stem cell biology, large cells such as cardiomyocytes, c. elegans eggs; organelles such as nuclei. Rachael can provide expertise in experimental setup, optimisation and analysis. She can help with optimal instrument set up, post-acquisition analysis of data and preparing figures for papers.

Education:

2005- PhD in Tissue Engineering, Department of Clinical Engineering, University of Liverpool
2001- BMedSc (Honours), Biomedical Materials Science, University of Birmingham

Flow Cytometry community

Rachael is very involved with the flow cytometry community on a local, national and international level.

Rachael’s work includes:

Awarded International Society for Advancement of Cytometry (ISAC) Scholarship 2012-2014

  • Awarded ISAC ‘Emerging Leader in Shared Resource Laboratory’ Scholarship 2014-2016
  • Mmeber of ISAC Flow Cytometry Content Task Force and SRL Emerging Leaders Committee
  • Member of ISAC Program committee for CYTO conferences since 2010
  • Chair of local Mid-Anglia Cytometry (MACC) meetings
  • Secretary of flowcytometryUK, also one of main organisers of flowcytometryUK national annual meetings
  • Fellow and member of Royal Microscopical Society (RMS) Cytometry Section
  • ​Regular contributor to ‘Flow Cytometry’ Channel on Bitesize Bio website.
  • Regular reviewer of papers for several journals and reviewer of international and national grants.

Latest Publications

Pantarelli C, Pan D, Chetwynd S, Stark AK, Hornigold K, Machin P, Crossland L, Cleary SJ, Baker MJ, Hampson E, Mandel A, Segonds-Pichon A, Walker R, van 't Veer C, Riffo-Vasquez Y, Okkenhaug K, Pitchford S, Welch HCE Signalling, Bioinformatics

Streptococcal pneumonia is a worldwide health problem that kills ∼2 million people each year, particularly young children, the elderly, and immunosuppressed individuals. Alveolar macrophages and neutrophils provide the early innate immune response to clear pneumococcus from infected lungs. However, the level of neutrophil involvement is context dependent, both in humans and in mouse models of the disease, influenced by factors such as bacterial load, age, and coinfections. Here, we show that the G protein-coupled receptor (GPCR) adaptor protein norbin (neurochondrin, NCDN), which was hitherto known as a regulator of neuronal function, is a suppressor of neutrophil-mediated innate immunity. Myeloid norbin deficiency improved the immunity of mice to pneumococcal infection by increasing the involvement of neutrophils in clearing the bacteria, without affecting neutrophil recruitment or causing autoinflammation. It also improved immunity during Escherichia coli-induced septic peritonitis. It increased the responsiveness of neutrophils to a range of stimuli, promoting their ability to kill bacteria in a reactive oxygen species-dependent manner, enhancing degranulation, phagocytosis, and the production of reactive oxygen species and neutrophil extracellular traps, raising the cell surface levels of selected GPCRs, and increasing GPCR-dependent Rac and Erk signaling. The Rac guanine-nucleotide exchange factor Prex1, a known effector of norbin, was dispensable for most of these effects, which suggested that norbin controls additional downstream targets. We identified the Rac guanine-nucleotide exchange factor Vav as one of these effectors. In summary, our study presents the GPCR adaptor protein norbin as an immune suppressor that limits the ability of neutrophils to clear bacterial infections.

+view abstract Blood advances, PMID: 34402884 24 Aug 2021

Back JB, Chadick CH, Garcia Vallejo JJ, Orlowski-Oliver E, Patel R, Roe CE, Srivastava J, Walker RV Flow Cytometry

Undoubtedly, the global pandemic caused by the SARS-CoV-2 virus has had a significant impact on Shared Resource Laboratories (SRL) operations worldwide. Unlike other crises (e.g. natural disasters, acts of war, or terrorism) which often result in a sudden and sustained cessation of scientific research usually affecting one or two cities at a time, this impact is being seen simultaneously in every SRL worldwide albeit to a varying degree. The alterations to SRL operations caused by the COVID-19 pandemic can generally be divided into three categories: i) complete shutdown, ii) partial shutdown, and iii) uninterrupted operations. In many cases SRLs which remained partially or fully operational during the initial wave of global infections saw a concurrent increase in COVID-19-related research coming through their facilities. This forced SRLs to make rapid adjustments to core operations at the same time as infectious disease experts were still developing recommendations for the safety of frontline medical workers. Although many SRLs already had contingency plans in place, this pandemic has highlighted the importance of having such plans for continuity of service, if possible, during a crisis. Immediate changes have occurred in the way SRLs operate due to potential virus transmission and in line with this new "Best Practices" have been established i.e. social distancing, remote working and technology-based meetings and training. Many of these changes are likely to be in place for some time with the threat of further waves of infections toward the end of 2020 and into 2021. Some of these best practices, such as having many training resources recorded and available online, are likely to remain long term. Although many changes have been made in haste, these will alter the future operations of SRLs. In addition we have learnt how to deal with future crises that may be encountered in the workplace.

+view abstract Cytometry, PMID: 33175466 11 Nov 2020

Czechowska K, Lannigan J, Aghaeepour N, Back JB, Begum J, Behbehani G, Bispo C, Bitoun D, Fernández AB, Boova ST, Brinkman RR, Ciccolella CO, Cotleur B, Davies D, Dela Cruz GV, Del Rio-Guerra R, Des Lauriers-Cox AM, Douagi I, Dumrese C, Bonilla Escobar DL, Estevam J, Ewald C, Fossum A, Gaudillière B, Green C, Groves C, Hall C, Haque Y, Hedrick MN, Hogg K, Hsieh EWY, Irish J, Lederer J, Leipold M, Lewis-Tuffin LJ, Litwin V, Lopez P, Nasdala I, Nedbal J, Ohlsson-Wilhelm BM, Price KM, Rahman AH, Rayanki R, Rieger AM, Robinson JP, Shapiro H, Sun YS, Tang VA, Tesfa L, Telford WG, Walker R, Welsh JA, Wheeler P, Tárnok A Flow Cytometry

See publication

+view abstract Cytometry, PMID: 31833655 Dec 2019

Group Members

Rachael Walker

Head of Flow Cytometry Facility

Larissa Catharina Costa

Flow Cytometry Technician

Yulia Chupalova

Flow Cytometry Specialist

Kleopatra Dagla

Flow Cytometry Assistant

Rita Dapaah

Flow Cytometry Technician

Christopher Hall

Deputy Flow Cytometry Manager

Sam Thompson

Flow Cytometry Specialist